Dr. Cherian Verghese, MD

Dr. Verghese practices at University Hospital (MU Health Care) in Columbia, Missouri.

Dr. Verghese's NPI, 1568548824, was assigned on October 30, 2006. Dr. Verghese holds Missouri license 2021031740.

Dr. Verghese's primary practice is University Hospital (MU Health Care), at 1 Hospital Dr, Columbia, MO 65201 in Boone County. The practice phone is (573) 882-4141.

Dr. Verghese's primary practice is University Hospital (MU Health Care) in Columbia, Missouri. Dr. Verghese is also affiliated with University Hospital. The medical group on file is University of Missouri Health Care. Dmand AI also links Dr. Verghese to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Verghese practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Verghese's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Verghese's licenses on file in 4 states: Missouri, Louisiana, Ohio and South Carolina.

CMS data shows 668 Medicare services from Dr. Verghese across 9 procedure codes in 2024, for 252 Medicare patients. Medicare paid $36,077 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 252 Medicare patients who saw Dr. Verghese in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have high blood pressure, and 58% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Verghese's median patient age at 70, with 53% women.

In 2024, Dr. Verghese wrote 818 Medicare Part D claims for 107 patients. 74% of them were for generic drugs. CMS names the drug for 632 of them, across 20 drugs with 11 or more claims each, at $1,560,643 in total drug cost. In 2023, CMS named 470 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Verghese for performance year 2024, reported as part of a group. Dr. Verghese accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Verghese, published from 2014 to 2024. 2017 was the busiest year, with 2. Dr. Verghese has published most often in Am J Ther. Dr. Verghese's most frequent co-authors are Francis Charles Brunicardi, MD, Lance D. Dworkin, MD and John Joseph Nemunaitis, MD.

Dmand AI links Dr. Verghese to 1 clinical trial. Conditions studied include Gliosarcoma and Glioblastoma. Open Payments lists research payments to Dr. Verghese that name 1 trial.

CMS Open Payments shows 51 general payments to Dr. Verghese from 30 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 47% of the total. ADC Therapeutics America, Inc. paid the most, $14,901. It also lists 1 research payment totaling $21 in 2017, naming 1 clinical trial.